SLC9A1 and breast carcinoma: Furthermore, overexpression of SLC9A1 reversed the inhibitory effects of ADMSC-derived exosomal miR-1236 on DDP resistance by activating the Wnt/β-Catenin signalling pathway in breast cancer [91].